Managing Drug Therapy

Blankenhorn D.H. (1991). Angiographic trials testing the efficacy of cholesterol lowering in reducing progression or inducing regression of coronary atherosclerosis. Coronary Artery Disease, 2, 875–879.

Blankenhorn D.H. Nessim S.A. Johnson R.L. Sammarco M.E. Azen S.P. , & Cashin-Hemphill L. (1987). Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass graft. JAMA, 257, 3233–3240.

Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. (1993). Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. (Adult Treatment Panel II). JAMA, 269(23), 3015–3023.

Hunninghake D.B. , & Peters J.R. (1987). Effect of fibric acid derivatives on blood lipid and lipoprotein levels. American Journal of Medicine, 83(5B), 44–49.

Illingworth D.R. Olsen G.D. Cook S.F. Sexton G.J. Wendel H.A. , & Connor W.E. (1982). Ciprofibrate in the therapy of type II hypercholesterolemia: A double-blind trial. Atherosclerosis, 44, 211–221.

Lipid Research Clinics Investigators. (1991). The Lipid Clinics Coronary Primary Prevention Trial: Results of 6 years of post-trial follow-up. Archives of Internal Medicine, 152, 1399–1410.

Lipid Research Clinics Program. (1984). The Lipid Research Clinics Coronary Primary Prevention Trial results. II: The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA, 251, 365–374.

Watts G.F. Lewis B. Brunt J.N.H. Coltart D.J. Smith L.D. Mann J.I. , & Swan A.V. (1992). Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine in the St. Thomas' Atherosclerosis Regression Study (STARS). Lancet, 339, 563–569.